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Objective. To determine the construct and crite-
rion validity of the British Isles Lupus Assessment
Group 2004 (BILAG-2004) index for assessing disease
activity in systemic lupus erythematosus (SLE).
Methods. Patients with SLE were recruited into a
multicenter cross-sectional study. Data on SLE disease
activity (scores on the BILAG-2004 index, Classic
BILAG index, and Systemic Lupus Erythematosus Dis-
ease Activity Index 2000 [SLEDAI-2K]), investigations,
and therapy were collected. Overall BILAG-2004 and
overall Classic BILAG scores were determined by the
highest score achieved in any of the individual systems
in the respective index. Erythrocyte sedimentation rates
(ESRs), C3 levels, C4 levels, anti–double-stranded DNA
(anti-dsDNA) levels, and SLEDAI-2K scores were used
in the analysis of construct validity, and increase in
therapy was used as the criterion for active disease in
the analysis of criterion validity. Statistical analyses
were performed using ordinal logistic regression for
construct validity and logistic regression for criterion
validity. Sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) were calcu-
lated.
Results. Of the 369 patients with SLE, 92.7% were
women, 59.9% were white, 18.4% were Afro-Caribbean
and 18.4% were South Asian. Their mean  SD age was
41.6  13.2 years and mean disease duration was 8.8 
7.7 years. More than 1 assessment was obtained on
88.6% of the patients, and a total of 1,510 assessments
were obtained. Increasing overall scores on the BILAG-
2004 index were associated with increasing ESRs, de-
creasing C3 levels, decreasing C4 levels, elevated anti-
dsDNA levels, and increasing SLEDAI-2K scores (all
P < 0.01). Increase in therapy was observed more
frequently in patients with overall BILAG-2004 scores
reflecting higher disease activity. Scores indicating ac-
tive disease (overall BILAG-2004 scores of A and B)
were significantly associated with increase in therapy
(odds ratio [OR] 19.3, P < 0.01). The BILAG-2004 and
Classic BILAG indices had comparable sensitivity,
specificity, PPV, and NPV.
Conclusion. These findings show that the BILAG-
2004 index has construct and criterion validity.
Assessment of disease activity in systemic lupus
erythematosus (SLE) is challenging in view of the ability
of SLE to affect any organ or system, resulting in diverse
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4113clinical manifestations. This is compounded by the lack
of a biomarker that uniformly reflects disease activity
well. As a result, numerous composite clinical indices
have been developed for standardized assessment of
disease activity (1).
The British Isles Lupus Assessment Group 2004
(BILAG-2004) index (2) was developed recently for the
assessment of disease activity in SLE, and it represents a
major revision of the Classic BILAG index (3). Like the
Classic BILAG index, it is a transitional index that is
able to capture changing severity of clinical manifesta-
tions. It is an ordinal scale index, which does not include
a global score but instead produces an overview of
disease activity across 9 systems. The interrater reliabil-
ity of this index has been established and described
elsewhere (2,4). The aim of this study was to determine
the construct and criterion validity of the BILAG-2004
index in assessment of SLE disease activity.
PATIENTS AND METHODS
Study design. This was a multicenter cross-sectional
study involving 8 centers in the UK. All patients included in the
study were diagnosed as having SLE according to the Ameri-
can College of Rheumatology criteria (5,6). Patients were
excluded from the study if they were pregnant, 18 years of
age, or unable to give valid consent. This study was carried out
in accordance with the Helsinki Declaration and received
multicenter research approval from the Hull and East Riding
Research Ethics Committee (Hull, UK) as well as approval
from the local research ethics committees of all participating
centers. Written consent was obtained from all patients.
The study was conducted from March 2005 to August
2006. At every assessment, data on disease activity, investiga-
tions, and treatment were collected. Disease activity was
assessed using the BILAG-2004 index, Classic BILAG index,
and Systemic Lupus Erythematosus Disease Activity Index
2000 (SLEDAI-2K) (7). All clinicians involved in this study
had been trained to use all 3 disease activity indices. More than
1 assessment was obtained on the majority of patients during
the study period.
Classic BILAG index. The BILAG index is an ordinal
scale index that assesses 8 systems (general, mucocutaneous,
neuropsychiatric, musculoskeletal, cardiorespiratory, vasculi-
tis, renal, and hematologic) (3). It was developed based on the
principle of physician’s intention to treat. Disease activity is
categorized into 5 different levels from A to E. Grade A
represents very active disease requiring immunosuppressive
drugs and/or 20 mg of prednisolone or equivalent daily.
Grade B represents moderately active disease requiring lower
doses of glucocorticoids, antimalarials, or nonsteroidal antiin-
flammatory drugs (NSAIDs). Grade C indicates mild stable
disease, while grade D indicates that there is no current disease
activity but that the system had previously been affected.
Grade E indicates no current or previous disease activity.
BILAG-2004 index. Like the Classic BILAG index, this
is an ordinal scale index based on the principle of physician’s
intention to treat. However, all of the items were revised and
reclassified into 9 systems (constitutional, mucocutaneous,
neuropsychiatric, musculoskeletal, cardiorespiratory, gastroin-
testinal, ophthalmic, renal, and hematologic). Disease activity
is scored from A to E, similar to the Classic BILAG index.
However, the scoring scheme was refined to reflect the fact
that anticoagulation (in combination with intensive immuno-
suppression), topical glucocorticoids or immunosuppressive
agents, thalidomide, prasterone, and retinoids may be used to
treat active manifestations. Therefore, grade A also includes
very active disease requiring anticoagulation therapy (in the
presence of immunosuppressive drugs or high-dose steroids),
and grade B also includes moderately active disease requiring
topical steroids, topical immunosuppressive agents, thalido-
mide, prasterone, or retinoids.
SLEDAI-2K. The SLEDAI-2K consists of 24 items, of
which 16 are clinical and 8 are based solely on laboratory
results (urinary casts, hematuria, proteinuria, pyuria, low com-
plement levels, increased DNA binding, thrombocytopenia,
and leukopenia) (7). A manifestation is recorded if it has been
present at any point during the past 10 days, regardless of
severity or whether it has improved or worsened. Weighting is
used, resulting in individual item scores ranging from 1 to 8
and a global score ranging from 0 to 105. In the present study,
items for which laboratory results were not available were
scored as negative or normal.
Statistical analysis. All statistical analyses were per-
formed using Stata for Windows, version 8 (StataCorp, College
Station, TX). For the purpose of the analysis, overall BILAG-
2004 and overall Classic BILAG scores were used. These
overall scores were determined by the highest score achieved
in any system in the respective index. BILAG-2004 and Classic
BILAG scores of D and E were combined, since both indicate
inactivity. Therefore, 4 categorical overall scores were possible
(A, B, C, and D).
Construct validity. The constructs used in this valida-
tion study were the erythrocyte sedimentation rate (ESR), C3
and C4 complement levels, anti–double-stranded DNA anti-
body (anti-dsDNA) level, and SLEDAI-2K score. It was
hypothesized that the overall score on the BILAG-2004 index
would have a positive correlation or association with the ESR,
anti-dsDNA level, and SLEDAI-2K score (since they increase
with disease activity), and a negative correlation or association
with complement C3 and C4 levels (since they decrease with
disease activity). ESR and levels of anti-dsDNA, C3, and C4
were determined locally at the participating centers. Since the
laboratory kits used were not the same in all centers, the
normal values for anti-dsDNA, C3, and C4 levels differed
among centers. Therefore, for the purpose of analysis, these
constructs were divided into ordinal categories. For ESR, the
categories were normal (0–30 mm/hour), elevated (31–60
mm/hour), and markedly elevated (60 mm/hour). For C3 and
C4 levels, the categories were normal, low, and very low (less
than or equal to half the lower limit of normal). For anti-
dsDNA level, the categories were normal, elevated, and very
high (5 times the upper limit of normal), and for
SLEDAI-2K score the categories were inactive (score of 0),
mildly active (scores of 1–3), active (scores of 4–12), and very
active (scores 12). The definitions of low C3 and C4 levels
and elevated dsDNA level varied depending on the study
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SLEDAI-2K scores as continuous variables.
Maximum-likelihood ordinal logistic regression was
used to assess construct validity, with overall BILAG-2004
score as the outcome variable and the constructs as the
explanatory variable. The normal or inactive category for each
construct was used as a baseline comparator for the other
categories. Since the majority of patients were assessed more
than once, independence of observations from the same pa-
tient could not be assumed. Therefore, robust variance esti-
mation (Huber/White/sandwich variance estimator) was used
instead of the standard maximum-likelihood variance estima-
tion (8). Results were reported as odds ratio (ORs) with 95%
confidence intervals (95% CIs).
Criterion validity. Since there is no absolute gold stan-
dard for disease activity in SLE, change in therapy was used as
the criterion. Change in therapy was defined as the difference
in therapy after the patient was assessed compared with the
therapy that the patient was receiving prior to assessment.
Three categories of change were defined, namely, no change,
increase in therapy, and decrease in therapy. Treatments of
interest were immunosuppressive agents, antimalarials, glu-
cocorticoids, biologic response modifiers, topical glucocorti-
coids, topical immunosuppressive agents, intravenous immu-
noglobulins, plasmapheresis, anticoagulation, prasterone,
thalidomide, and retinoids. NSAIDs were not included since
they were commonly used for several other indications and
could be obtained without a prescription.
Increase in therapy was defined as any increase in the
medications of interest regardless of any concomitant reduc-
tion in other medications. Decrease in therapy was defined as
any decrease in the medications of interest without any con-
comitant increase in other medications. However, change in
therapy was not just a simple change in the dosage of the
medications. Several special circumstances had to be taken
into account. For some immunosuppressive agents, different
dosing levels based on body weight were used in the definition
of change in therapy. A change in therapy was deemed to have
occurred when there was a change in the dosing level of these
medications. A change in immunosuppressive therapy was
generally considered to be an increase in therapy, except in the
case of changing from cyclophosphamide to azathioprine,
methotrexate, or cyclosporin A. This is because it is common
practice to make such a change once the disease is under
control (the step-down phase), since prolonged cyclo-
phosphamide therapy is associated with significant toxicity.
Therefore, this step-down phase was equivalent to a reduction
in therapy, since the discontinuation of cyclophosphamide was
considered to be a decrease in therapy while the initiation of
the other immunosuppressive agent was not considered an
increase.
When treatment was changed from cyclophosphamide
to mycophenolate mofetil, the local investigator was contacted
to determine whether the change was a result of treatment
failure with cyclophosphamide (indicating increase in therapy)
or was used in a step-down phase (indicating no increase in
therapy). If an immunosuppressive agent was started for
steroid-sparing effect, this was not considered to be an increase
in therapy. Anticoagulation therapy had to be initiated due to
active disease (which was clarified with the local investigator)
and in the presence of immunosuppressive agents or high-dose
steroids, in order to be considered an increase in therapy.
Because most immunosuppressive agents have poten-
tial toxic effects, it is common practice to start treatment at a
low dosage and gradually escalate to the target dosage. To take
this into account, any increase in the dosage of immunosup-
pressive agents within the first 3 months of initiation was
considered to be part of an escalation plan to achieve the
target dose and was not considered an increase in therapy.
Similarly, it is common practice to gradually reduce the
glucocorticoid dosage during this period as part of the escala-
tion plan. Therefore, any concomitant reduction in glucocor-
ticoid dosage during the escalation phase was not considered
to be a reduction in therapy. The reduction or discontinuation
of any treatment due to side effects was not considered to be
a reduction in therapy.
For this analysis, disease activity was divided into
active disease (scores of A or B on the BILAG-2004 index or
the Classic BILAG index) and minimal activity (scores of C or
D on the BILAG-2004 index or the Classic BILAG index).
Similarly, change in therapy was classified into 2 categories,
“increase in therapy” and “no increase in therapy.” Therefore,
“no increase in therapy” represented a combination of no
change and decrease in therapy. The categories were defined
in this way because increase in therapy was a better marker of
disease activity than decrease in therapy. In practice, increase
in therapy is very likely to occur with active disease and is
unlikely to occur with inactive disease. The reverse cannot be
said for reduction in therapy, since this is less likely to occur
with inactive disease when the patient is receiving minimal
therapy (such as low-dose glucocorticoids).
Maximum-likelihood logistic regression with robust
variance estimation (Huber/White/sandwich variance estima-
tor) was used with increase in therapy as the outcome variable
and overall BILAG-2004 score as the explanatory variable.
Results were reported as ORs and 95% CIs. Sensitivity,
specificity, positive predictive value (PPV), and negative pre-
dictive value (NPV) of the overall BILAG-2004 score against
the criterion were calculated from the regression analysis. For
calculation of sensitivity, only observations which recorded an
increase in treatment were used. A logistic regression model
(with robust variance estimation) was fitted to the subset of
data with overall BILAG-2004 scores as the response variable,
and the intercept term was determined. This intercept term
represents the sensitivity, and the 95% CI was calculated using
the robust estimate of the intercept’s standard error. Specific-
ity, PPV, and NPV were calculated in a similar manner, using
only a subset of observations (those indicating no increase in
treatment, those indicating active disease, or those indicating
minimally active disease, respectively). A similar analysis was
performed using the Classic BILAG index for comparison.
RESULTS
Patients. A total of 1,510 assessments were ob-
tained in 369 SLE patients. The mean  SD age of the
patients was 41.6  13.2 years, and the mean disease
duration was 8.8  7.7 years. Most of the patients
(92.7%) were women. The majority of the patients
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18.4% were South Asian. More than 1 assessment was
obtained from 88.6% of the patients during the study
period. The distribution of disease activity and con-
structs (cross-tabulated against disease activity) are sum-
marized in Tables 1 and 2.
Constructs. ESR. ESRs were available for 787
assessments (52.1%). There was a significant association
between increasing ESR and overall BILAG-2004 scores
reflecting higher disease activity (Table 3). The 2 de-
grees of freedom test for an association between overall
BILAG-2004 score and ESR was statistically significant
(P  0.001).When ESR was analyzed as a continuous
variable, the result was similar (P  0.0002).
Anti-dsDNA level. Anti-dsDNA levels were avail-
able for 1,413 assessments (93.6%). Increasing levels of
anti-dsDNA were significantly associated with overall
BILAG-2004 scores reflecting high disease activity (Ta-
ble 3). The 2 degrees of freedom test for an association
between overall BILAG-2004 score and anti-dsDNA
was statistically significant (P  0.0008).
C3 and C4 levels. C3 and C4 levels were available
for 1,463 assessments (96.9%) and 1,366 assessments
(90.5%), respectively. There was a significant association
between lower C3 levels and overall BILAG-2004 scores
reflecting higher disease activity and between lower C4
levels and overall BILAG-2004 scores reflecting higher
disease activity (Table 3). For both models, the 2
degrees of freedom test was statistically significant (P 
0.0001).
SLEDAI-2K score. SLEDAI-2K scores were
available for all assessments. Higher SLEDAI-2K scores
were significantly associated with overall BILAG-2004
scores reflecting higher disease activity (Table 3). The 3
degrees of freedom test for an association between
overall BILAG-2004 score and SLEDAI-2K score was
significant (P  0.001). Results were similar when
SLEDAI-2K score was analyzed as a continuous variable
(P  0.0001).
Multivariate analysis. For completeness, we per-
formed a multivariate analysis with ESR, anti-dsDNA
level, C3 level, and C4 level included in the same
regression model. Only increasing ESR and low C4 level
remained significantly associated with overall BILAG-
2004 scores reflecting higher disease activity.
Table 2. Cross-tabulation of overall scores on the BILAG-2004
index with constructs (ESR, anti-dsDNA level, C3 level, C4 level, and
SLEDAI-2K score)*
Construct
Overall score on the
BILAG-2004 index
AB C D
ESR
Normal (0–30 mm/hour) 29 158 267 100
Elevated (31–60 mm/hour) 23 60 70 15
Markedly elevated (60 mm/
hour)
13 25 20 7
Anti-dsDNA level
Normal 49 228 506 216
Elevated 25 100 119 66
Very high (5 times the ULN) 15 38 42 9
C3 level
Normal 61 279 579 270
Very low (less than or equal to
half the LLN)
4460
Low 29 100 106 25
C4 level
Normal 44 218 467 243
Very low (less than or equal to
half the LLN)
25 49 51 6
Low 18 76 132 37
SLEDAI-2K score
Inactive (0) 2 22 306 194
Mildly active (1–3) 4 93 240 82
Active (4–12) 75 264 175 25
Very active (12) 17 11 0 0
* Values are the number of assessments. Data were available on
erythrocyte sedimentation rates (ESRs) for 787 assessments, anti–
double-stranded DNA (anti- dsDNA) levels for 1,413 assessments, C3
levels for 1,463 assessments, C4 levels for 1,366 assessments, and
Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-
2K) scores for all 1,510 assessments. BILAG-2004  British Isles
Lupus Assessment Group 2004; ULN  upper limit of normal; LLN 
lower limit of normal.
Table 1. Distribution of disease activity scores on the BILAG-2004
index, Classic BILAG index, and SLEDAI-2K*
Disease activity score
No. (%) of
assessments (n  1,510
assessments in
369 patients)
Overall score on the
BILAG-2004 index
A 98 (6.5)
B 390 (25.8)
C 721 (47.8)
D 301 (19.9)
Overall score on the Classic
BILAG index
A 95 (6.3)
B 435 (28.8)
C 834 (55.2)
D 146 (9.7)
SLEDAI-2K score
12 28 (1.9)
4–12 539 (35.7)
1–3 419 (27.7)
0 524 (34.7)
* The overall score on the British Isles Lupus Assessment Group 2004
(BILAG-2004) index and on the Classic BILAG index was the highest
score achieved in any system in the index. SLEDAI-2K  Systemic
Lupus Erythematosus Disease Activity Index 2000.
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(22.6%) resulted in an increase in therapy, 320 (21.2%)
resulted in a decrease in therapy, and 848 (56.2%) were
not followed by a change in therapy (Table 4). The odds
of an increase in therapy were higher with overall
BILAG-2004 scores reflecting higher disease activity
(Table 5).
Sensitivity and specificity. Scores indicating ac-
tive disease (overall scores on the BILAG-2004 of A and
B) were significantly associated with an increase in
therapy (OR 19.3 [95% CI 14.1–26.4]). The sensitivity,
specificity, PPV, and NPV of the BILAG-2004 index are
summarized in Table 6. The BILAG-2004 index and the
Classic BILAG index had equivalent sensitivity, speci-
ficity, PPV, and NPV.
DISCUSSION
The results of this large multicenter cross-
sectional study demonstrated the validity of the BILAG-
2004 index as a measure of SLE disease activity, based
on its construct and criterion validity. Construct validity
was confirmed by the expected association between
index scores and the ESR, C3 level, C4 level, anti-
dsDNA level, and SLEDAI-2K score. Criterion validity
was confirmed by the increasing strength of association
between BILAG-2004 scores reflecting increasing dis-
ease activity and increase in therapy.
The results of the multivariate analysis of con-
struct validity were rather surprising, since we expected
elevated anti-dsDNA level and/or C3 level, instead of
elevated ESR and C4 level, to remain significantly
associated with increasing overall scores on the BILAG-
2004 index. Because this was a cross-sectional study, it
was not possible to determine why there was an associ-
ation between increased disease activity in SLE, as
measured by the BILAG-2004 index score, and low C4
level but not low C3 level in the multivariate analysis. It
should be noted that low levels of C4 have previously
been found to be a predictor of renal flare (9). Further-
more, low C4 levels have been found to be associated
with the presence of anti-Ro antibodies and major
histocompatibility complex haplotype B8;C4AQ0;DR2;
DQ2, which could predispose to skin, pulmonary, and
neurologic involvement (10–15). A longitudinal study is
Table 4. Cross-tabulation of overall scores on the BILAG-2004
index with change in therapy*
Overall score on the
BILAG-2004 index
Change in therapy
Decrease No change Increase
D 83 213 4
C 197 464 61
B 38 147 205
A 2 24 72
* Values are the number of assessments. BILAG-2004  British Isles
Lupus Assessment Group 2004.
Table 5. Association of increase in therapy with overall score on the
BILAG-2004 index*
Overall score on the
BILAG-2004 index OR (95% CI)
A 204.9 (65.6–639.9)
B 82.0 (29.9–225.0)
C 6.8 (2.4–19.1)
* BILAG-2004  British Isles Lupus Assessment Group 2004; OR 
odds ratio; 95% CI  95% confidence interval.
Table 6. Sensitivity, specificity, positive predictive value, and nega-
tive predictive value of the BILAG-2004 index and Classic BILAG
index*
BILAG-2004 index Classic BILAG index
Sensitivity, % 81.0 (76.4–84.9) 83.6 (79.1–87.3)
Specificity, % 81.9 (78.4–85.0) 79.1 (75.5–82.3)
PPV, % 56.8 (51.7–61.7) 54.0 (49.3–58.6)
NPV, % 93.6 (91.9–95.0) 94.3 (92.6–95.6)
* Values in parentheses are the 95% confidence interval. BILAG 
British Isles Lupus Assessment Group; PPV  positive predictive
value; NPV  negative predictive value.
Table 3. Association of ESR, anti-dsDNA level, C3 level, C4 level,
and SLEDAI-2K score with higher overall scores on the BILAG-2004
index*
Construct OR (95% CI)
ESR
Elevated (31–60 mm/hour) 2.1 (1.4–3.0)
Markedly elevated (60 mm/hour) 2.9 (1.4–6.2)
Anti-dsDNA level
Elevated 1.5 (0.99–2.1)
Very high (5 times the ULN) 2.7 (1.6–4.8)
C3 level
Very low (less than or equal to
half the LLN)
5.0 (1.6–15.5)
Low 2.5 (1.8–3.5)
C4 level
Very low (less than or equal to
half the LLN)
4.2 (2.5–6.9)
Low 1.7 (1.2–2.3)
SLEDAI-2K score
Mildly active (1–3) 3.0 (2.1–4.4)
Active (4–12) 20.0 (13.6–29.5)
Very active (12) 232.7 (108.4–499.2)
* The overall score on the BILAG-2004 index was the highest score
achieved in any system in the index. OR  odds ratio; 95% CI  95%
confidence interval (see Table 2 for other definitions).
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between a reduction in C4 levels and an increase in
disease activity in SLE as measured by the BILAG-2004
index.
The BILAG-2004 index was developed as an
ordinal scale index, and the scores for individual systems
were not intended to be summed into a global score.
Therefore, for the purpose of validation, the best way to
represent overall disease activity in any individual pa-
tient was to use the highest score achieved in any system
within the index. This is logical, since a patient with any
system scoring grade A or B should be categorized as
having active disease (requiring therapy in principle),
regardless of how many systems have a score of A or B.
From an analysis viewpoint, this may put the BILAG-
2004 index at a disadvantage, since there is a ceiling
effect, which may underestimate the severity of the
illness. For example, a patient with 5 systems scoring B
will have the same overall score as a patient with only 1
system scoring B. However, for clinical trials and out-
come studies, it may be appropriate to consider the
number of systems with a given categorical score in the
analysis.
Change in therapy was chosen as the gold stan-
dard for designating disease as active, in the absence of
a better alternative. Physician’s global assessment has
been used previously as a benchmark, but several studies
have shown this to be unsatisfactory, with poor agree-
ment between physicians (16–19). Although the BILAG-
2004 index was developed on the basis of the principle of
physician’s intention to treat, use of change in therapy as
the criterion for active disease should not explicitly bias
the analysis in favor of the index, since actual change in
therapy does not determine the scoring. Only the pres-
ence of manifestations of active disease influences the
scoring. Furthermore, the patient’s score on the index
was not available to the physician when the treatment
decision was made, and it is difficult to calculate the
score on the BILAG-2004 index in routine clinical
practice without the appropriate reference documents.
One of the limitations of this study is inherent in
the cross-sectional design, in that it only accounts for
disease activity in SLE at the time of assessment. This
does not take into account the level of disease activity
prior to the assessment, which influences treatment
decisions. The treatment decision regarding a patient
with active disease is very different if prior disease
activity was low (such as a change from grade D to B)
when treatment would be increased, than if prior disease
activity was high (such as a change from grade A to B)
when treatment would not be increased and, in fact,
might be decreased.
Making a treatment decision is a complex process
that involves consideration of several factors apart from
the physician’s intent to treat. Such factors include
current therapy, previous therapy (and its effect), the
patient’s opinion (in particular, refusal to change ther-
apy as advised), and the presence of comorbid condi-
tions. Unfortunately, it was not possible to model all of
these factors in the present study. This may explain the
relatively low PPV of the BILAG-2004 index. On the
other hand, the high NPV is reassuring, since this
indicates that increase in therapy is very unlikely in the
absence of high disease activity as measured by the
BILAG-2004 index.
It is not surprising that the BILAG-2004 index
and the Classic BILAG index had similar sensitivity,
specificity, PPV, and NPV, since the main difference
between the 2 indices is the addition of ophthalmic and
gastrointestinal manifestations in the BILAG-2004 in-
dex. Active disease manifestations in these 2 systems
were not common in this study; there were only 6
assessments (from 5 patients) with a score of A or B in
the gastrointestinal system and 8 assessments (from 3
patients) with a score of A or B in the ophthalmic
system. Although these manifestations are uncommon,
they are significant and important for individual patients
and need to be captured.
In conclusion, the BILAG-2004 index is a valid
measure of disease activity in SLE. It is more compre-
hensive, incorporates more up-to-date terminology, and
has a clearer glossary of definitions than the Classic
BILAG index. Therefore, we recommend that the
BILAG-2004 index be considered for use in clinical trials
and outcome studies of SLE.
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